Icon snaps up molecular Dx specialist MolecularMD for undisclosed price

Laboratory
The purchase expands Icon’s laboratory offering in molecular diagnostic testing. (Getty/RossHelen)

Icon, a CRO based in Dublin, has acquired MolecularMD, a molecular diagnostic specialty lab that focuses on a platform for the development and commercialization of precision medicines for oncology.

Financial terms of the deal weren’t disclosed.

The purchase expands Icon’s laboratory offering in molecular diagnostic testing and brings expanded testing platforms, including next generation sequencing and immunohistochemistry (IHC), the company said.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

MolecularMD, which was founded in 2006, offers a comprehensive test menu in the area of immune oncology development at its labs in Portland, Oregon, and Cambridge, Massachusetts. The company also offers companion diagnostic development services.

“We are committed to expanding the testing we offer into specialized areas so that we can help customers to take time and cost from the development and commercialization of precision medicines,” Steve Cutler, Icon’s CEO, said in a statement.

RELATED: Irish CRO Icon rolls out digital platform developed with Dimension Data

Last month, Icon adopted a new digital platform developed with Dimension Data that was designed to enhance efficiency and productivity of its client’s drug and medical device pipelines. The platform was rolled out throughout the CRO to help support digital trials and patient interactions.

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.